[424B5] Neuphoria Therapeutics Inc. Prospectus Supplement (Debt Securities)
Neuphoria Therapeutics (NEUP) filed Amendment No. 6 to its prospectus supplement for its at-the-market program, permitting sales of up to $21,917,873 of common stock from time to time through H.C. Wainwright as sales agent.
Sales will be effected as an “at the market” offering under Rule 415(a)(4). Wainwright will receive a 3.0% commission on gross proceeds and will be deemed an underwriter; indemnification and contribution apply. The company states compliance with General Instruction I.B.6 of Form S‑3: public float was approximately $65,753,620 based on 3,287,681 non‑affiliate shares at $20.00 as of October 6, 2025, and it has sold $15,477,836 over the past 12 months under I.B.6.
The common stock trades on Nasdaq as NEUP; the last reported sale price was $6.24 on October 24, 2025.
Neuphoria Therapeutics (NEUP) ha depositato l'Ammendamento n. 6 al suo supplemento al prospetto per il programma at-the-market, che consente vendite fino a $21,917,873 di azioni comuni di volta in volta tramite H.C. Wainwright come agente di vendita.
Le vendite saranno effettuate come offerta "at the market" ai sensi della Regola 415(a)(4). Wainwright riceverà una commissione del 3,0% sul ricavato lordo e sarà considerato un collocatore; è prevista indennità e contributo. L'azienda dichiara di conformarsi alle Istruzioni Generali I.B.6 del Form S‑3: il flottante pubblico era di circa $65,753,620 basato su 3,287,681 azioni non affiliate a $20,00 al 6 ottobre 2025, e ha venduto $15,477,836 nei ultimi 12 mesi ai sensi di I.B.6.
Le azioni comuni sono negoziate su Nasdaq con il simbolo NEUP; l'ultimo prezzo di vendita riportato è stato di $6.24 il 24 ottobre 2025.
Neuphoria Therapeutics (NEUP) presentó la Enmienda n. 6 a su suplemento de prospecto para su programa at-the-market, permitiendo ventas de hasta $21,917,873 de acciones ordinarias de forma intermitente a través de H.C. Wainwright como agente de ventas.
Las ventas se efectuarán como una oferta “at the market” bajo la Regla 415(a)(4). Wainwright recibirá una comisión del 3.0% sobre los ingresos brutos y se le considerará un suscriptor; se aplican indemnización y contribución. La empresa señala cumplimiento con la Instrucción General I.B.6 del Formulario S‑3: el float público era de aproximadamente $65,753,620 basado en 3,287,681 acciones no afiliadas a $20.00 al 6 de octubre de 2025, y ha vendido $15,477,836 en los últimos 12 meses conforme a I.B.6.
Las acciones ordinarias cotizan en Nasdaq como NEUP; el último precio de venta reportado fue de $6.24 el 24 de octubre de 2025.
Neuphoria Therapeutics (NEUP)는 현장 시장 매수 프로그램의 제6차 수정안을 제출했으며, H.C. Wainwright를 판매 대리인으로 하여 필요 시 $21,917,873까지의 보통주를 판매할 수 있습니다.
매출은 Rule 415(a)(4)에 따른 시장 내(off-the-market) 형태의 공모로 이루어지며, Wainwright는 총수익의 3.0%의 수수료를 받고 언더라이더로 간주되며 배상 및 분담이 적용됩니다. 회사는 Form S-3의 일반 지침 I.B.6에 따라 공모가 $65,753,620의 퍼블릭 플로트가 2025년 10월 6일 기준 비관련 주식 3,287,681주에 대해 $20.00로 산정되며, 지난 12개월간 I.B.6에 따라 $15,477,836를 매도했다고 밝혔습니다.
일반 주식은 Nasdaq에서 NEUP로 거래되며, 마지막 보고된 매도가 $6.24는 2025년 10월 24일자입니다.
Neuphoria Therapeutics (NEUP) a déposé l’A amendment n° 6 de son supplément de prospectus pour son programme de placement à l’office, autorisant des ventes allant jusqu’à $21,917,873 d’actions ordinaires de temps à autre par l’intermédiaire de H.C. Wainwright en tant qu’agent de vente.
Les ventes seront effectuées comme une offre « at the market » en vertu de la règle 415(a)(4). Wainwright recevra une commission de 3,0% sur le produit brut et sera considéré comme un preneur de valeurs; l’indemnisation et la contribution s’appliquent. La société déclare sa conformité à l’Instruction générale I.B.6 du Form S‑3: le flottant public était d’environ $65,753,620 basé sur 3,287,681 actions non affiliées à $20,00 au 6 octobre 2025, et elle a vendu $15,477,836 au cours des 12 derniers mois selon I.B.6.
Les actions ordinaires sont négociées sur Nasdaq sous le symbole NEUP; le dernier prix de vente signalé était de $6.24 le 24 octobre 2025.
Neuphoria Therapeutics (NEUP) hat Amendment Nr. 6 zu seinem Prospekt-Supplement für das Market-at-the-Market-Programm eingereicht, das Verkäufe von bis zu $21,917,873 an Stammaktien von Zeit zu Zeit über H.C. Wainwright als Verkaufsagent erlaubt.
Verkäufe werden als „at the market“-Angebot gemäß Regel 415(a)(4) durchgeführt. Wainwright erhält eine Bruttoprovision von 3,0% und gilt als Underwriter; Freistellung und Beitrag gelten. Das Unternehmen erklärt die Einhaltung der Allgemeinen Anweisung I.B.6 des Form S-3: Public Float betrug gemäß 3.287.681 nicht verbundene Aktien bei $20,00 am 6. Oktober 2025 ungefähr $65,753,620, und es hat in den letzten 12 Monaten gemäß I.B.6 $15,477,836 verkauft.
Die Stammaktien werden an der Nasdaq als NEUP gehandelt; der zuletzt berichtete Verkaufspreis betrug $6.24 am 24. Oktober 2025.
Neuphoria Therapeutics (NEUP) قدمت التعديل رقم 6 إلى ملحق نشرتها للبرنامج السوقي، مما يسمح ببيع حتى $21,917,873 من الأسهم العادية من حين لآخر عبر H.C. Wainwright كوكيل مبيعات.
سيتم البيع كعرض "at the market" بموجب القاعدة 415(a)(4). ستتلقى Wainwright عمولة قدرها 3.0% من الإيرادات الإجمالية وسيُعتبر مُدْعِمًا؛ وسيُطبق التعويض والمساهمة. تقول الشركة إنها تلتزم بالتعليمات العامة I.B.6 من النموذج S-3: كان الفلتان العام حوالي $65,753,620 بناءً على 3,287,681 سهم غير تابع عند 20.00 دولار حتى 6 أكتوبر 2025، وباعَت $15,477,836 خلال الـ12 شهراً الماضية وفقاً لـ I.B.6.
تتم التداول في Nasdaq بالرمز NEUP; آخر سعر بيع مُبلغ عنه كان $6.24 في 24 أكتوبر 2025.
- None.
- None.
Neuphoria Therapeutics (NEUP) ha depositato l'Ammendamento n. 6 al suo supplemento al prospetto per il programma at-the-market, che consente vendite fino a $21,917,873 di azioni comuni di volta in volta tramite H.C. Wainwright come agente di vendita.
Le vendite saranno effettuate come offerta "at the market" ai sensi della Regola 415(a)(4). Wainwright riceverà una commissione del 3,0% sul ricavato lordo e sarà considerato un collocatore; è prevista indennità e contributo. L'azienda dichiara di conformarsi alle Istruzioni Generali I.B.6 del Form S‑3: il flottante pubblico era di circa $65,753,620 basato su 3,287,681 azioni non affiliate a $20,00 al 6 ottobre 2025, e ha venduto $15,477,836 nei ultimi 12 mesi ai sensi di I.B.6.
Le azioni comuni sono negoziate su Nasdaq con il simbolo NEUP; l'ultimo prezzo di vendita riportato è stato di $6.24 il 24 ottobre 2025.
Neuphoria Therapeutics (NEUP) presentó la Enmienda n. 6 a su suplemento de prospecto para su programa at-the-market, permitiendo ventas de hasta $21,917,873 de acciones ordinarias de forma intermitente a través de H.C. Wainwright como agente de ventas.
Las ventas se efectuarán como una oferta “at the market” bajo la Regla 415(a)(4). Wainwright recibirá una comisión del 3.0% sobre los ingresos brutos y se le considerará un suscriptor; se aplican indemnización y contribución. La empresa señala cumplimiento con la Instrucción General I.B.6 del Formulario S‑3: el float público era de aproximadamente $65,753,620 basado en 3,287,681 acciones no afiliadas a $20.00 al 6 de octubre de 2025, y ha vendido $15,477,836 en los últimos 12 meses conforme a I.B.6.
Las acciones ordinarias cotizan en Nasdaq como NEUP; el último precio de venta reportado fue de $6.24 el 24 de octubre de 2025.
Neuphoria Therapeutics (NEUP)는 현장 시장 매수 프로그램의 제6차 수정안을 제출했으며, H.C. Wainwright를 판매 대리인으로 하여 필요 시 $21,917,873까지의 보통주를 판매할 수 있습니다.
매출은 Rule 415(a)(4)에 따른 시장 내(off-the-market) 형태의 공모로 이루어지며, Wainwright는 총수익의 3.0%의 수수료를 받고 언더라이더로 간주되며 배상 및 분담이 적용됩니다. 회사는 Form S-3의 일반 지침 I.B.6에 따라 공모가 $65,753,620의 퍼블릭 플로트가 2025년 10월 6일 기준 비관련 주식 3,287,681주에 대해 $20.00로 산정되며, 지난 12개월간 I.B.6에 따라 $15,477,836를 매도했다고 밝혔습니다.
일반 주식은 Nasdaq에서 NEUP로 거래되며, 마지막 보고된 매도가 $6.24는 2025년 10월 24일자입니다.
Neuphoria Therapeutics (NEUP) a déposé l’A amendment n° 6 de son supplément de prospectus pour son programme de placement à l’office, autorisant des ventes allant jusqu’à $21,917,873 d’actions ordinaires de temps à autre par l’intermédiaire de H.C. Wainwright en tant qu’agent de vente.
Les ventes seront effectuées comme une offre « at the market » en vertu de la règle 415(a)(4). Wainwright recevra une commission de 3,0% sur le produit brut et sera considéré comme un preneur de valeurs; l’indemnisation et la contribution s’appliquent. La société déclare sa conformité à l’Instruction générale I.B.6 du Form S‑3: le flottant public était d’environ $65,753,620 basé sur 3,287,681 actions non affiliées à $20,00 au 6 octobre 2025, et elle a vendu $15,477,836 au cours des 12 derniers mois selon I.B.6.
Les actions ordinaires sont négociées sur Nasdaq sous le symbole NEUP; le dernier prix de vente signalé était de $6.24 le 24 octobre 2025.
Neuphoria Therapeutics (NEUP) hat Amendment Nr. 6 zu seinem Prospekt-Supplement für das Market-at-the-Market-Programm eingereicht, das Verkäufe von bis zu $21,917,873 an Stammaktien von Zeit zu Zeit über H.C. Wainwright als Verkaufsagent erlaubt.
Verkäufe werden als „at the market“-Angebot gemäß Regel 415(a)(4) durchgeführt. Wainwright erhält eine Bruttoprovision von 3,0% und gilt als Underwriter; Freistellung und Beitrag gelten. Das Unternehmen erklärt die Einhaltung der Allgemeinen Anweisung I.B.6 des Form S-3: Public Float betrug gemäß 3.287.681 nicht verbundene Aktien bei $20,00 am 6. Oktober 2025 ungefähr $65,753,620, und es hat in den letzten 12 Monaten gemäß I.B.6 $15,477,836 verkauft.
Die Stammaktien werden an der Nasdaq als NEUP gehandelt; der zuletzt berichtete Verkaufspreis betrug $6.24 am 24. Oktober 2025.
Neuphoria Therapeutics (NEUP) قدمت التعديل رقم 6 إلى ملحق نشرتها للبرنامج السوقي، مما يسمح ببيع حتى $21,917,873 من الأسهم العادية من حين لآخر عبر H.C. Wainwright كوكيل مبيعات.
سيتم البيع كعرض "at the market" بموجب القاعدة 415(a)(4). ستتلقى Wainwright عمولة قدرها 3.0% من الإيرادات الإجمالية وسيُعتبر مُدْعِمًا؛ وسيُطبق التعويض والمساهمة. تقول الشركة إنها تلتزم بالتعليمات العامة I.B.6 من النموذج S-3: كان الفلتان العام حوالي $65,753,620 بناءً على 3,287,681 سهم غير تابع عند 20.00 دولار حتى 6 أكتوبر 2025، وباعَت $15,477,836 خلال الـ12 شهراً الماضية وفقاً لـ I.B.6.
تتم التداول في Nasdaq بالرمز NEUP; آخر سعر بيع مُبلغ عنه كان $6.24 في 24 أكتوبر 2025.
Neuphoria Therapeutics (NEUP) 已提交其招股说明书补充资料的修订案第6号，适用于其市场在售计划，允许通过销售代理人H.C. Wainwright不时出售多达$21,917,873股普通股。
销售将作为“在市场内”发行，依据 Rule 415(a)(4) 进行。Wainwright 将就毛收入获得3.0%的佣金，并将被视为承销商；适用赔偿与分担。公司表示遵守表格 S-3 的通用指示 I.B.6：公开浮动约为$65,753,620，基于 3,287,681 股非关联股份，股价为 $20.00（截至 2025 年 10 月 6 日），在过去 12 个月内按 I.B.6 已出售 $15,477,836。
普通股在纳斯达克交易，代码为 NEUP；最近披露的成交价为 $6.24，日期为 2025 年 10 月 24 日。
Filed pursuant to Rule 424(b)(5)
Registration No. 333-283306
AMENDMENT NO. 6, dated October 27, 2025
to PROSPECTUS SUPPLEMENT dated January 6, 2025
Up to $21,917,873
Common Stock
This Amendment No. 6 to Prospectus Supplement (this “Amendment”) amends and updates our prospectus supplement, dated January 6, 2025, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3, File No. 333-283306 (the “Prospectus Supplement”). This Amendment should be read in conjunction with the Prospectus Supplement and the accompanying prospectus dated January 6, 2025 (the “Prospectus”), each of which are to be delivered with this Amendment, as well as any of our SEC filings which amend, supplement and update this Prospectus Supplement. This Amendment amends and/or updates only those sections of the Prospectus Supplement set forth in this Amendment (other than as automatically updated and amended by the Company’s SEC filings available on Edgar, which are incorporated by reference herein). In addition, we refer persons or entities considering making an investment in our securities to also to review information contained in that certain Schedule 13D filed with the SEC on October 23, 2025, which can be found on the SEC’s website regarding Neuphoria Therapeutics Inc. at: www.sec.gov, which discloses a significant accumulation of shares of our common stock in open market transactions shortly preceding the date of such Schedule 13D filing by an investment fund; all other sections of the Prospectus Supplement remain unchanged. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement, and any future amendments or supplements hereto or thereto.
We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated November 18, 2024. Under this Sales Agreement, as updated by this Amendment, we may offer and sell common stock having an aggregate offering price of up to $ $21,917,873 from time to time through Wainwright, acting as sales agent, in accordance with the Sales Agreement, less any amounts previously sold during the past 12 months, as delineated below.
Sales of the common stock, if any, under this prospectus, as amended, may be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Wainwright may sell our common stock by any method permitted by law deemed to be an at-the-market offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Wainwright is not required to sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent with their normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq, on mutually agreed terms between the Wainwright and us. There are no minimum sale requirements, and there is no arrangement for funds to be received in any escrow, trust or similar arrangement.
We are filing this Amendment to amend the Prospectus Supplement to update the amount of shares of common stock we are eligible to sell under General Instruction I.B.6 of Form S-3 and pursuant to the Sales Agreement. The aggregate market value of our common stock held by non-affiliates, or public float, was approximately $65,753,620 based on 3,287,681 non-affiliate shares of common stock outstanding, based on a closing price of $20.00 per share on October 6, 2025, which was the highest closing sale price of our common stock on the Nasdaq Global Market, the principal market for our common equity, within 60 days of the filing date of this registration statement, as amended. In the past 12 calendar months, we have offered and sold an aggregate of $15,477,836 of shares of our common stock pursuant to General Instruction I.B.6 of Form S-3. In no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.
Wainwright will be entitled to a commission of 3.0% of the gross sales price per share sold under the Sales Agreement. See “Plan of Distribution” beginning on page S-11 of our prospectus supplement, dated January 6, 2025 for additional information regarding the compensation to be paid to Wainwright. In connection with the sale of the common stock on our behalf, Wainwright will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation paid to Wainwright will be deemed to be underwriting compensation. We have also agreed in the Sales Agreement to provide indemnification and contribution to Wainwright with respect to certain liabilities, including liabilities under the Securities Act.
Our common stock is listed on the Nasdaq under the symbol “NEUP.” On October 24, 2025, the last reported sale price of our common stock on the Nasdaq was $6.24 per share.
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. BEFORE MAKING AN INVESTMENT DECISION, PLEASE READ THE INFORMATION UNDER THE HEADING “RISK FACTORS” BEGINNING ON PAGE S-6 OF THE PROSPECTUS SUPPLEMENT INCLUDED IN THIS REGISTRATION STATEMENT, AND IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS SUPPLEMENT.
Neither the Securities and Exchange Commission, any state securities commission, nor any other foreign securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this Amendment No. 6 to prospectus supplement is October 27, 2025.
